Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dodick

Showing results (361-370 of 620) with videos related to

Pageof 62
Sort By:
Pain and Therapy|October 7, 2020
The Impact of OnabotulinumtoxinA vs. Placebo on Efficacy Outcomes in Headache Day Responder and Nonresponder Patients with Chronic MigraineStephen D Silberstein, Hans-Christoph Diener, David W Dodick, et al.
Headache|September 2, 2017
Fremanezumab as Add-On Treatment for Patients Treated With Other Migraine Preventive MedicinesJoshua M Cohen, David W Dodick, Ronghua Yang, et al.
Headache|January 18, 2006
Oral sumatriptan for the acute treatment of probable migraine: first randomized, controlled studyStewart J Tepper, Roger Cady, David Dodick, et al.
Neurology|March 2, 2012
Randomized, placebo-controlled trial of propranolol added to topiramate in chronic migraineS D Silberstein, D W Dodick, A S Lindblad, et al.
Cephalalgia : an International Journal of Headache|December 17, 2011
Lack of drug interaction between the migraine drug MAP0004 (orally inhaled dihydroergotamine) and a CYP3A4 inhibitor in humansD Kellerman, S Kori, A Forst, et al.
Headache|April 8, 2017
Insights into the Functional Anatomy Behind the PREEMPT Injection Paradigm: Guidance on Achieving Optimal OutcomesAndrew M Blumenfeld, Stephen D Silberstein, David W Dodick, et al.
Cephalalgia : an International Journal of Headache|March 7, 2020
Acute treatment patterns in patients with migraine newly initiating a triptanRichard B Lipton, Steven C Marcus, Anand R Shewale, et al.
Pain and Therapy|October 7, 2020
Benefits Beyond Headache Days With OnabotulinumtoxinA Treatment: A Pooled PREEMPT AnalysisHans-Christoph Diener, David W Dodick, Richard B Lipton, et al.
Headache|May 22, 2018
Use of Most Bothersome Symptom as a Coprimary Endpoint in Migraine Clinical Trials: A Post-Hoc Analysis of the Pivotal ZOTRIP Randomized, Controlled TrialDavid W Dodick, Stewart J Tepper, Deborah I Friedman, et al.
Headache|June 26, 2020
Open-Label, Multi-Dose, Pilot Safety Study of Injection of OnabotulinumtoxinA Toward the Otic Ganglion for the Treatment of Intractable Chronic Cluster HeadacheJoan Crespi, Daniel Bratbak, David W Dodick, et al.
Pageof 62

Showing results (361-370 of 620) with videos related to

Sort By:
Pageof 62
Pain and Therapy|October 7, 2020
The Impact of OnabotulinumtoxinA vs. Placebo on Efficacy Outcomes in Headache Day Responder and Nonresponder Patients with Chronic MigraineStephen D Silberstein, Hans-Christoph Diener, David W Dodick, et al.
Headache|September 2, 2017
Fremanezumab as Add-On Treatment for Patients Treated With Other Migraine Preventive MedicinesJoshua M Cohen, David W Dodick, Ronghua Yang, et al.
Headache|January 18, 2006
Oral sumatriptan for the acute treatment of probable migraine: first randomized, controlled studyStewart J Tepper, Roger Cady, David Dodick, et al.
Neurology|March 2, 2012
Randomized, placebo-controlled trial of propranolol added to topiramate in chronic migraineS D Silberstein, D W Dodick, A S Lindblad, et al.
Cephalalgia : an International Journal of Headache|December 17, 2011
Lack of drug interaction between the migraine drug MAP0004 (orally inhaled dihydroergotamine) and a CYP3A4 inhibitor in humansD Kellerman, S Kori, A Forst, et al.
Headache|April 8, 2017
Insights into the Functional Anatomy Behind the PREEMPT Injection Paradigm: Guidance on Achieving Optimal OutcomesAndrew M Blumenfeld, Stephen D Silberstein, David W Dodick, et al.
Cephalalgia : an International Journal of Headache|March 7, 2020
Acute treatment patterns in patients with migraine newly initiating a triptanRichard B Lipton, Steven C Marcus, Anand R Shewale, et al.
Pain and Therapy|October 7, 2020
Benefits Beyond Headache Days With OnabotulinumtoxinA Treatment: A Pooled PREEMPT AnalysisHans-Christoph Diener, David W Dodick, Richard B Lipton, et al.
Headache|May 22, 2018
Use of Most Bothersome Symptom as a Coprimary Endpoint in Migraine Clinical Trials: A Post-Hoc Analysis of the Pivotal ZOTRIP Randomized, Controlled TrialDavid W Dodick, Stewart J Tepper, Deborah I Friedman, et al.
Headache|June 26, 2020
Open-Label, Multi-Dose, Pilot Safety Study of Injection of OnabotulinumtoxinA Toward the Otic Ganglion for the Treatment of Intractable Chronic Cluster HeadacheJoan Crespi, Daniel Bratbak, David W Dodick, et al.
Pageof 62